Aravive Investor Presentation Deck
Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other
Cancer Therapies
&
GAS6/AXL signaling drives metastasis and
drug-resistance. ARAV is the only company
targeting GAS6.
Wealth of preclinical studies demonstrate
ability to combine with common standards of
care to allow access to a large total
accessible market
Robust chemistry manufacturing control
with high yield and purity; dovetails with
clinical to allow for BLA end of 2023
Well-tolerated to date and no anticipated
drug-drug interactions facilitate combination
studies (unlike small molecules); serum
biomarker may accelerate development
and identify patients with best chance of
response
Fast-track designation granted by the FDA for
platinum-resistant ovarian cancer; currently
in registrational Phase 3 trial with topline
data due middle 2023 and potential BLA
end 2023
Currently in P1b/2 ccRCC; agreed
registrational study with the FDA
incorporates interim analysis for
accelerated approval potential
Currently in P1b Pancreatic Adenocarcinoma
Cancer (PDAC) study; pk/pd analysis
suggests higher doses should be tested
3View entire presentation